As we mark Omic's first year, we're excited to share the progress we've made building our AI-driven drug discovery platform.
Building the Foundation
Since our founding in 2017, we've been heads-down building the core technology that will power our drug discovery efforts:
- Omic Data Engine: A scalable infrastructure for ingesting, normalizing, and analyzing multi-omics datasets across public and proprietary sources
- BioReason: Our first-generation AI system for biological hypothesis generation and testing
- Integration framework: APIs connecting to major biological databases including GEO, TCGA, and UniProt
Growing the Team
We've expanded from our founding team to 6 people, bringing together expertise in:
- Machine Learning - Advancing our AI architectures
- Computational Biology - Guiding biological modeling
- Data Engineering - Scaling our data infrastructure
- Software Engineering - Building robust, production systems
The Bootstrapped Approach
We've chosen to build Omic as a bootstrapped company. This decision reflects our belief that transforming drug discovery requires long-term thinking, not short-term metrics driven by external funding pressures.
Being self-funded means:
- Patient capital: We can invest in hard problems without pressure for quick exits
- Aligned incentives: Our success depends entirely on building technology that works
- Sustainable growth: We grow as our technology proves itself
What's Next
Our immediate priorities include:
- Expanding our multi-omics data corpus to over 1 million patient samples
- Validating our target discovery AI on known drug targets
- Beginning pilot programs with pharmaceutical partners
We're building something that hasn't existed before—AI that truly understands biology. Our bootstrapped approach gives us the freedom to do it right.
Omic is a self-funded company headquartered in San Francisco.
Omic - Building Biological Superintelligence to End Disease